Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative On
about
Implications of Insulin-like Growth Factor 1 Receptor Activation in Lung CancerDalotuzumab in chemorefractory KRAS exon 2 mutant colorectal cancer: Results from a randomised phase II/III trial.Adverse Events and Efficacy of Cixutumumab in Phase II Clinical Trials: A systematic Review and Meta-Analysis.Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapyInsights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?Non-small-cell lung cancer: molecular targeted therapy and personalized medicine - drug resistance, mechanisms, and strategiesAnti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy.Long-lasting response to third-line crizotinib treatment in a patient with non-small cell lung cancer with brain metastases and poor performance status.Phase II randomized trial of carboplatin, paclitaxel, bevacizumab with or without cixutumumab (IMC-A12) in patients with advanced non-squamous, non-small-cell lung cancer: a trial of the ECOG-ACRIN Cancer Research Group (E3508).
P2860
Q26740210-E8CAA501-3237-4495-8016-8177681F4990Q30313824-52B05E68-863F-4E42-8F82-2B6A00DA6088Q33436873-D36CD9AE-CCEC-403D-964B-5B4C1B170A59Q33710179-F5B3E891-ADA8-4773-A71A-E24CAF9D0AFCQ36322851-E1393685-AB28-408D-BF8E-0AFE2BABD420Q36850900-72E62770-E59A-4A59-B487-90A4099BA813Q38763641-8911D25B-0FAD-45A1-921C-BC0941DD8F46Q39337110-9C6A1609-CFF9-4B5B-904C-36E6A5BFBE67Q42339666-A7FD5761-8D0C-461A-BA28-690142F19680Q49820985-132623B5-C458-43E3-BD18-627E3E320885
P2860
Three-arm, randomized, phase 2 study of carboplatin and paclitaxel in combination with cetuximab, cixutumumab, or both for advanced non-small cell lung cancer (NSCLC) patients who will not receive bevacizumab-based therapy: An Eastern Cooperative On
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Three-arm, randomized, phase 2 ...... apy: An Eastern Cooperative On
@ast
Three-arm, randomized, phase 2 ...... apy: An Eastern Cooperative On
@en
type
label
Three-arm, randomized, phase 2 ...... apy: An Eastern Cooperative On
@ast
Three-arm, randomized, phase 2 ...... apy: An Eastern Cooperative On
@en
prefLabel
Three-arm, randomized, phase 2 ...... apy: An Eastern Cooperative On
@ast
Three-arm, randomized, phase 2 ...... apy: An Eastern Cooperative On
@en
P2093
P2860
P921
P356
P1433
P1476
Three-arm, randomized, phase 2 ...... ogy Group (ECOG) study (E4508)
@en
P2093
Charu Aggarwal
Fred R Hirsch
Jill M Kolesar
Joan H Schiller
Nasser H Hanna
Suresh S Ramalingam
P2860
P304
P356
10.1002/CNCR.29308
P407
P577
2015-03-04T00:00:00Z